Your browser doesn't support javascript.
loading
NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.
Ma, Chi; Kesarwala, Aparna H; Eggert, Tobias; Medina-Echeverz, José; Kleiner, David E; Jin, Ping; Stroncek, David F; Terabe, Masaki; Kapoor, Veena; ElGindi, Mei; Han, Miaojun; Thornton, Angela M; Zhang, Haibo; Egger, Michèle; Luo, Ji; Felsher, Dean W; McVicar, Daniel W; Weber, Achim; Heikenwalder, Mathias; Greten, Tim F.
Afiliação
  • Ma C; Gastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
  • Kesarwala AH; Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
  • Eggert T; Gastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
  • Medina-Echeverz J; Gastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
  • Kleiner DE; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
  • Jin P; Cell Processing Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA.
  • Stroncek DF; Cell Processing Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA.
  • Terabe M; Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
  • Kapoor V; Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
  • ElGindi M; Gastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
  • Han M; Gastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
  • Thornton AM; Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
  • Zhang H; Laboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
  • Egger M; Institute of Surgical Pathology, University and University Hospital Zurich, Zurich 8091, Switzerland.
  • Luo J; Laboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
  • Felsher DW; Division of Oncology, Department of Medicine and Pathology, Stanford University, California 94305, USA.
  • McVicar DW; Cancer and Inflammation Program, National Cancer Institute, Frederick, Maryland 21702, USA.
  • Weber A; Institute of Surgical Pathology, University and University Hospital Zurich, Zurich 8091, Switzerland.
  • Heikenwalder M; Institute of Virology, Technische Universität München/Helmholtz Zentrum München, Munich 81675, Germany.
  • Greten TF; Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.
Nature ; 531(7593): 253-7, 2016 Mar 10.
Article em En | MEDLINE | ID: mdl-26934227
ABSTRACT
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death. Non-alcoholic fatty liver disease (NAFLD) affects a large proportion of the US population and is considered to be a metabolic predisposition to liver cancer. However, the role of adaptive immune responses in NAFLD-promoted HCC is largely unknown. Here we show, in mouse models and human samples, that dysregulation of lipid metabolism in NAFLD causes a selective loss of intrahepatic CD4(+) but not CD8(+) T lymphocytes, leading to accelerated hepatocarcinogenesis. We also demonstrate that CD4(+) T lymphocytes have greater mitochondrial mass than CD8(+) T lymphocytes and generate higher levels of mitochondrially derived reactive oxygen species (ROS). Disruption of mitochondrial function by linoleic acid, a fatty acid accumulated in NAFLD, causes more oxidative damage than other free fatty acids such as palmitic acid, and mediates selective loss of intrahepatic CD4(+) T lymphocytes. In vivo blockade of ROS reversed NAFLD-induced hepatic CD4(+) T lymphocyte decrease and delayed NAFLD-promoted HCC. Our results provide an unexpected link between lipid dysregulation and impaired anti-tumour surveillance.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos T CD4-Positivos / Carcinoma Hepatocelular / Carcinogênese / Hepatopatia Gordurosa não Alcoólica / Neoplasias Hepáticas Tipo de estudo: Etiology_studies / Observational_studies Idioma: En Revista: Nature Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos T CD4-Positivos / Carcinoma Hepatocelular / Carcinogênese / Hepatopatia Gordurosa não Alcoólica / Neoplasias Hepáticas Tipo de estudo: Etiology_studies / Observational_studies Idioma: En Revista: Nature Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos